Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

PNPLA 3 I148M genetic var… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection.

Artikel i vetenskaplig tidskrift
Författare Karolina Rembeck
Cristina Maglio
Martin Lagging
Peer Brehm Christensen
Martti Färkkilä
Nina Langeland
Mads Rauning Buhl
Court Pedersen
Kristine Mørch
Gunnar Norkrans
Kristoffer Hellstrand
Magnus Lindh
Carlo Pirazzi
Maria Antonella Burza
Stefano Romeo
Johan Westin
Publicerad i BMC medical genetics
Volym 13
Nummer/häfte 1
Sidor 82
ISSN 1471-2350
Publiceringsår 2012
Publicerad vid Institutionen för biomedicin, avdelningen för infektionssjukdomar
Institutionen för medicin, avdelningen för molekylär och klinisk medicin
Sidor 82
Språk en
Länkar dx.doi.org/10.1186/1471-2350-13-82
https://gup.ub.gu.se/file/86412
Ämnesord Hepatitis C, PNPLA 3, Insulin resistance, Viral load
Ämneskategorier Medicinska grundvetenskaper

Sammanfattning

ABSTRACT: BACKGROUND: Hepatic steatosis in HCV patients has been postulated as a risk factor associated with a higher frequency of fibrosis and cirrhosis. A single genetic variant, PNPLA3 I148M, has been widely associated with increased hepatic steatosis. Previous studies of the PNPLA3 I148M sequence variant in HCV infected individuals have reported an association between this variant and prevalence of steatosis, fibrosis, and cirrhosis. To evaluate the impact of PNPLA3 I148M variant on metabolic traits and treatment response in HCV genotype 2 and 3 infected patients. METHODS: Three hundred and eighty-two treatment naive HCV genotype 2 or 3 infected patients were included in a phase III, open label, randomized, multicenter, investigator-initiated trial (the NORDynamIC study), in which pretreatment liver biopsies were mandatory. PNPLA3I148M genotyping was performed in a total of 359 Caucasian patients. RESULTS: In HCV genotype 2 infected patients carrying the PNPLA3 148 M allele, there was significantly increased insulin resistance (P = 0.023) and lower viral load (P = 0.005) at baseline as well as the first seven days of antiviral treatment. These results were not observed in HCV genotype 3 infected patients. CONCLUSIONS: Our results suggest a possible association between the PNPLA3 148 M allele and insulin resistance as well as baseline viral load in HCV genotype 2, but not in genotype 3.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?